{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:16:39Z","timestamp":1791432999533,"version":"4.3.3"},"reference-count":148,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":1421,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"NIH, NINDS","award":["5R01NS062856"],"award-info":[{"award-number":["5R01NS062856"]}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"crossref","award":["1R01EY026490"],"award-info":[{"award-number":["1R01EY026490"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"crossref","award":["1R01EY029166"],"award-info":[{"award-number":["1R01EY029166"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002108","name":"Friedreich\u2019s Ataxia Research Alliance","doi-asserted-by":"crossref","award":["not known"],"award-info":[{"award-number":["not known"]}],"id":[{"id":"10.13039\/100002108","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical, Inc","doi-asserted-by":"crossref","award":["not known"],"award-info":[{"award-number":["not known"]}],"id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s13311-019-00764-x","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T15:42:38Z","timestamp":1563378158000},"page":"1032-1049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Molecular Mechanisms and Therapeutics for the GAA\u00b7TTC Expansion Disease Friedreich Ataxia"],"prefix":"10.1016","volume":"16","author":[{"given":"Joel M.","family":"Gottesfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1007\/s13311-019-00764-x_bib1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nrg2748","article-title":"Repeat expansion disease: progress and puzzles in disease pathogenesis","volume":"11","author":"La Spada","year":"2010","journal-title":"Nat Rev Genet."},{"key":"10.1007\/s13311-019-00764-x_bib2","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1146\/annurev.neuro.29.051605.113042","article-title":"Trinucleotide repeat disorders","volume":"30","author":"Orr","year":"2007","journal-title":"Annual Review of Neuroscience."},{"key":"10.1007\/s13311-019-00764-x_bib3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/B978-0-444-63233-3.00009-9","article-title":"Repeat expansion diseases","volume":"147","author":"Paulson","year":"2018","journal-title":"Handbook of Clinical Neurology"},{"issue":"6","key":"10.1007\/s13311-019-00764-x_bib4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrn.2016.38","article-title":"The expanding biology of the C9orf72 nucleotide repeat expansion in neurodegenerative disease","volume":"17","author":"Haeusler","year":"2016","journal-title":"Nat Rev Neurosci."},{"issue":"11","key":"10.1007\/s13311-019-00764-x_bib5","doi-asserted-by":"crossref","first-page":"e49083","DOI":"10.1371\/journal.pone.0049083","article-title":"A common trinucleotide repeat expansion within the transcription factor 4 (TCF4, E2-2) gene predicts Fuchs corneal dystrophy","volume":"7","author":"Wieben","year":"2012","journal-title":"PLoS One."},{"key":"10.1007\/s13311-019-00764-x_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.gde.2017.01.005","article-title":"RNA toxicity and foci formation in microsatellite expansion diseases","volume":"44","author":"Zhang","year":"2017","journal-title":"Curr Opin Genet Dev."},{"key":"10.1007\/s13311-019-00764-x_bib7","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1074\/jbc.M114.621607","article-title":"RNA toxicity and missplicing in the common eye disease Fuchs endothelial corneal dystrophy","volume":"290","author":"Du","year":"2015","journal-title":"J Biol Chem."},{"key":"10.1007\/s13311-019-00764-x_bib8","doi-asserted-by":"crossref","first-page":"16127","DOI":"10.1074\/jbc.R118.003237","article-title":"Repeat-associated non-ATG (RAN) translation","volume":"293","author":"Cleary","year":"2018","journal-title":"J Biol Chem."},{"key":"10.1007\/s13311-019-00764-x_bib9","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fneur.2015.00262","article-title":"Epigenetics and triplet-repeat neurological diseases","volume":"6","author":"Nageshwaran","year":"2015","journal-title":"Front Neurol."},{"issue":"5254","key":"10.1007\/s13311-019-00764-x_bib10","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","article-title":"Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion","volume":"271","author":"Campuzano","year":"1996","journal-title":"Science"},{"issue":"5","key":"10.1007\/s13311-019-00764-x_bib11","first-page":"1251","article-title":"Atypical Friedreich ataxia caused by compound heterozygosity for a novel missense mutation and the GAA triplet-repeat expansion","volume":"60","author":"Bidichandani","year":"1997","journal-title":"Am J Hum Genet."},{"issue":"4","key":"10.1007\/s13311-019-00764-x_bib12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10048-007-0101-5","article-title":"Frataxin gene point mutations in Italian Friedreich ataxia patients","volume":"8","author":"Gellera","year":"2007","journal-title":"Neurogenetics"},{"issue":"4","key":"10.1007\/s13311-019-00764-x_bib13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000198417","article-title":"Friedreich's ataxia: a new mutation in two compound heterozygous siblings with unusual clinical onset","volume":"61","author":"Lamba","year":"2009","journal-title":"European neurology."},{"issue":"7","key":"10.1007\/s13311-019-00764-x_bib14","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1001\/archneurol.2011.834","article-title":"Exonic deletions of FXN and early-onset Friedreich ataxia","volume":"69","author":"Anheim","year":"2012","journal-title":"Arch Neurol."},{"key":"10.1007\/s13311-019-00764-x_bib15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40673-017-0062-x","article-title":"Friedreich ataxia: current status and future prospects","volume":"4","author":"Burk","year":"2017","journal-title":"Cerebellum & ataxias."},{"issue":"7","key":"10.1007\/s13311-019-00764-x_bib16","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1136\/jnnp.2003.028605","article-title":"Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of Friedreich ataxia patients and carriers","volume":"75","author":"Pianese","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"1","key":"10.1007\/s13311-019-00764-x_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1086\/301680","article-title":"The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure","volume":"62","author":"Bidichandani","year":"1998","journal-title":"Am J Hum Genet."},{"issue":"52","key":"10.1007\/s13311-019-00764-x_bib18","doi-asserted-by":"crossref","first-page":"36773","DOI":"10.1074\/jbc.M113.525857","article-title":"Frataxin directly stimulates mitochondrial cysteine desulfurase by exposing substrate-binding sites, and a mutant Fe-S cluster scaffold protein with frataxin-bypassing ability acts similarly","volume":"288","author":"Pandey","year":"2013","journal-title":"J Biol Chem."},{"issue":"5681","key":"10.1007\/s13311-019-00764-x_bib19","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1126\/science.1098991","article-title":"Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity","volume":"305","author":"Bulteau","year":"2004","journal-title":"Science"},{"issue":"4","key":"10.1007\/s13311-019-00764-x_bib20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/hmg\/ddi042","article-title":"Friedreich ataxia: the oxidative stress paradox","volume":"14","author":"Seznec","year":"2005","journal-title":"Hum Mol Genet."},{"issue":"1\u20132","key":"10.1007\/s13311-019-00764-x_bib21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jns.2005.03.012","article-title":"Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia","volume":"233","author":"Calabrese","year":"2005","journal-title":"J Neurol Sci."},{"issue":"4","key":"10.1007\/s13311-019-00764-x_bib22","first-page":"502","article-title":"Mortality in Friedreich's ataxia","volume":"34","author":"Lynch","year":"2007","journal-title":"Tex Heart Inst J."},{"issue":"23","key":"10.1007\/s13311-019-00764-x_bib23","doi-asserted-by":"crossref","first-page":"14588","DOI":"10.1074\/jbc.273.23.14588","article-title":"Inhibitory effects of expanded GAA.TTC triplet repeats from intron I of the Friedreich ataxia gene on transcription and replication in vivo","volume":"273","author":"Ohshima","year":"1998","journal-title":"J Biol Chem."},{"issue":"3","key":"10.1007\/s13311-019-00764-x_bib24","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s004150050198","article-title":"Determinants of onset age in Friedreich's ataxia","volume":"245","author":"De Michele","year":"1998","journal-title":"J Neurol."},{"issue":"1","key":"10.1007\/s13311-019-00764-x_bib25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ajhg.2008.06.018","article-title":"Influence of Friedreich ataxia GAA noncoding repeat expansions on pre-mRNA processing","volume":"83","author":"Baralle","year":"2008","journal-title":"Am J Hum Genet."},{"issue":"10","key":"10.1007\/s13311-019-00764-x_bib26","doi-asserted-by":"crossref","first-page":"e47847","DOI":"10.1371\/journal.pone.0047847","article-title":"Novel frataxin isoforms may contribute to the pathological mechanism of Friedreich ataxia","volume":"7","author":"Xia","year":"2012","journal-title":"PLoS One."},{"issue":"16","key":"10.1007\/s13311-019-00764-x_bib27","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1073\/pnas.1716617115","article-title":"Intron retention induced by microsatellite expansions as a disease biomarker","volume":"115","author":"Sznajder","year":"2018","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"4","key":"10.1007\/s13311-019-00764-x_bib28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/emmm.201000064","article-title":"Long intronic GAA repeats causing Friedreich ataxia impede transcription elongation","volume":"2","author":"Punga","year":"2010","journal-title":"EMBO Mol Med."},{"key":"10.1007\/s13311-019-00764-x_bib29","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/ana.24260","article-title":"Epigenetic therapy for Friedreich's ataxia","volume":"76","author":"Soragni","year":"2014","journal-title":"Ann Neurol."},{"issue":"4","key":"10.1007\/s13311-019-00764-x_bib30","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1097-2765(00)80474-8","article-title":"Sticky DNA: self-association properties of long GAA.TTC repeats in R.R.Y triplex structures from Friedreich's ataxia","volume":"3","author":"Sakamoto","year":"1999","journal-title":"Mol Cell."},{"issue":"29","key":"10.1007\/s13311-019-00764-x_bib31","doi-asserted-by":"crossref","first-page":"27171","DOI":"10.1074\/jbc.M101879200","article-title":"Sticky DNA, a self-associated complex formed at long GAA*TTC repeats in intron 1 of the frataxin gene, inhibits transcription","volume":"276","author":"Sakamoto","year":"2001","journal-title":"J Biol Chem."},{"issue":"31","key":"10.1007\/s13311-019-00764-x_bib32","doi-asserted-by":"crossref","first-page":"11497","DOI":"10.1073\/pnas.0604939103","article-title":"DNA sequence-specific polyamides alleviate transcription inhibition associated with long GAA.TTC repeats in Friedreich's ataxia","volume":"103","author":"Burnett","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"24","key":"10.1007\/s13311-019-00764-x_bib33","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1093\/nar\/28.24.4930","article-title":"Alleviating transcript insufficiency caused by Friedreich's ataxia triplet repeats","volume":"28","author":"Grabczyk","year":"2000","journal-title":"Nucleic Acids Res."},{"issue":"14","key":"10.1007\/s13311-019-00764-x_bib34","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1093\/nar\/28.14.2815","article-title":"The GAA*TTC triplet repeat expanded in Friedreich's ataxia impedes transcription elongation by T7 RNA polymerase in a length and supercoil dependent manner","volume":"28","author":"Grabczyk","year":"2000","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1007\/s13311-019-00764-x_bib35","doi-asserted-by":"crossref","first-page":"e1004318","DOI":"10.1371\/journal.pgen.1004318","article-title":"R-loops associated with triplet repeat expansions promote gene silencing in Friedreich ataxia and fragile X syndrome","volume":"10","author":"Groh","year":"2014","journal-title":"PLoS Genet."},{"key":"10.1007\/s13311-019-00764-x_bib36","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.tig.2009.04.007","article-title":"Instability and chromatin structure of expanded trinucleotide repeats","volume":"25","author":"Dion","year":"2009","journal-title":"Trends Genet."},{"issue":"11","key":"10.1007\/s13311-019-00764-x_bib37","doi-asserted-by":"crossref","first-page":"e7914","DOI":"10.1371\/journal.pone.0007914","article-title":"Epigenetic silencing in friedreich ataxia is associated with depletion of CTCF (CCCTC-binding factor) and antisense transcription","volume":"4","author":"De Biase","year":"2009","journal-title":"PLoS One"},{"key":"10.1007\/s13311-019-00764-x_bib38","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1126\/science.1163853","article-title":"The antisense transcriptomes of human cells","volume":"322","author":"He","year":"2008","journal-title":"Science"},{"issue":"9","key":"10.1007\/s13311-019-00764-x_bib39","doi-asserted-by":"crossref","first-page":"e74956","DOI":"10.1371\/journal.pone.0074956","article-title":"Friedreich ataxia patient tissues exhibit increased 5-hydroxymethylcytosine modification and decreased CTCF binding at the FXN locus","volume":"8","author":"Al-Mahdawi","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1007\/s13311-019-00764-x_bib40","doi-asserted-by":"crossref","first-page":"17217","DOI":"10.1038\/s41598-018-35639-2","article-title":"FAST-1 antisense RNA epigenetically alters FXN expression","volume":"8","author":"Mikaeili","year":"2018","journal-title":"Sci Rep."},{"key":"10.1007\/s13311-019-00764-x_bib41","doi-asserted-by":"crossref","first-page":"10606","DOI":"10.1038\/ncomms10606","article-title":"Activating frataxin expression by repeat-targeted nucleic acids","volume":"7","author":"Li","year":"2016","journal-title":"Nat Commun."},{"key":"10.1007\/s13311-019-00764-x_bib42","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.cell.2018.06.044","article-title":"RNA-dependent epigenetic silencing directs transcriptional downregulation caused by intronic repeat expansions","volume":"174","author":"Eimer","year":"2018","journal-title":"Cell"},{"issue":"6934","key":"10.1007\/s13311-019-00764-x_bib43","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nature01596","article-title":"DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing","volume":"422","author":"Saveliev","year":"2003","journal-title":"Nature"},{"issue":"23","key":"10.1007\/s13311-019-00764-x_bib44","doi-asserted-by":"crossref","first-page":"R895","DOI":"10.1016\/j.cub.2003.11.006","article-title":"Heterochromatin: silence is golden","volume":"13","author":"Elgin","year":"2003","journal-title":"Curr Biol."},{"issue":"10","key":"10.1007\/s13311-019-00764-x_bib45","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nchembio815","article-title":"Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia","volume":"2","author":"Herman","year":"2006","journal-title":"Nat Chem Biol."},{"key":"10.1007\/s13311-019-00764-x_bib46","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1093\/nar\/gkm271","article-title":"Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia","volume":"35","author":"Greene","year":"2007","journal-title":"Nucl Acids Res."},{"key":"10.1007\/s13311-019-00764-x_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fgene.2014.00165","article-title":"Epigenetic-based therapies for Friedreich ataxia","volume":"5","author":"Sandi","year":"2014","journal-title":"Front Genet."},{"issue":"Suppl 1","key":"10.1007\/s13311-019-00764-x_bib48","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/jnc.12254","article-title":"Gene regulation and epigenetics in Friedreich's ataxia","volume":"126","author":"Yandim","year":"2013","journal-title":"J Neurochem."},{"issue":"5","key":"10.1007\/s13311-019-00764-x_bib49","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/hmg\/ddm346","article-title":"The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues","volume":"17","author":"Al-Mahdawi","year":"2008","journal-title":"Hum Mol Genet."},{"key":"10.1007\/s13311-019-00764-x_bib50","doi-asserted-by":"crossref","first-page":"e1958","DOI":"10.1371\/journal.pone.0001958","article-title":"HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model","volume":"3","author":"Rai","year":"2008","journal-title":"PLoS ONE"},{"issue":"19","key":"10.1007\/s13311-019-00764-x_bib51","doi-asserted-by":"crossref","first-page":"8366","DOI":"10.1093\/nar\/gkr542","article-title":"Hyperexpansion of GAA repeats affects post-initiation steps of FXN transcription in Friedreich's ataxia","volume":"39","author":"Kim","year":"2011","journal-title":"Nucleic Acids Res."},{"issue":"13","key":"10.1007\/s13311-019-00764-x_bib52","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1093\/hmg\/ddt115","article-title":"Heterochromatinization induced by GAA-repeat hyperexpansion in Friedreich's ataxia can be reduced upon HDAC inhibition by vitamin B3","volume":"22","author":"Chan","year":"2013","journal-title":"Hum Mol Genet."},{"issue":"4","key":"10.1007\/s13311-019-00764-x_bib53","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/ana.22671","article-title":"FXN methylation predicts expression and clinical outcome in Friedreich ataxia","volume":"71","author":"Evans-Galea","year":"2012","journal-title":"Ann Neurol."},{"issue":"12","key":"10.1007\/s13311-019-00764-x_bib54","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/jmg.2008.058594","article-title":"DNA methylation in intron 1 of the frataxin gene is related to GAA repeat length and age of onset in Friedreich ataxia patients","volume":"45","author":"Castaldo","year":"2008","journal-title":"J Med Genet."},{"issue":"12","key":"10.1007\/s13311-019-00764-x_bib55","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/ng.471","article-title":"Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts","volume":"41","author":"Doi","year":"2009","journal-title":"Nat Genet."},{"issue":"2","key":"10.1007\/s13311-019-00764-x_bib56","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/ng.298","article-title":"The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores","volume":"41","author":"Irizarry","year":"2009","journal-title":"Nat Genet."},{"key":"10.1007\/s13311-019-00764-x_bib57","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3727\/000000001783992731","article-title":"DNA methylation and histone deacetylation in the control of gene expression: basic biochemistry to human development and disease","volume":"9","author":"El-Osta","year":"2000","journal-title":"Gene Expr."},{"key":"10.1007\/s13311-019-00764-x_bib58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3389\/fneur.2015.00044","article-title":"Mechanism of action of 2-aminobenzamide HDAC inhibitors in reversing gene silencing in Friedreich's ataxia","volume":"6","author":"Soragni","year":"2015","journal-title":"Front Neurol."},{"issue":"12","key":"10.1007\/s13311-019-00764-x_bib59","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1093\/hmg\/ddv096","article-title":"Expanded GAA repeats impair FXN gene expression and reposition the FXN locus to the nuclear lamina in single cells","volume":"24","author":"Silva","year":"2015","journal-title":"Hum Mol Genet."},{"issue":"7","key":"10.1007\/s13311-019-00764-x_bib60","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.cell.2012.04.035","article-title":"DNA sequence-dependent compartmentalization and silencing of chromatin at the nuclear lamina","volume":"149","author":"Zullo","year":"2012","journal-title":"Cell"},{"issue":"6","key":"10.1007\/s13311-019-00764-x_bib61","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1074\/jbc.M110.194035","article-title":"Repeat expansion affects both transcription initiation and elongation in friedreich ataxia cells","volume":"286","author":"Kumari","year":"2011","journal-title":"J Biol Chem."},{"issue":"22","key":"10.1007\/s13311-019-00764-x_bib62","doi-asserted-by":"crossref","first-page":"15194","DOI":"10.1074\/jbc.M114.566414","article-title":"Altered nucleosome positioning at the transcription start site and deficient transcriptional initiation in Friedreich ataxia","volume":"289","author":"Chutake","year":"2014","journal-title":"J Biol Chem."},{"issue":"4","key":"10.1007\/s13311-019-00764-x_bib63","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/ana.24249","article-title":"Epigenetic promoter silencing in Friedreich ataxia is dependent on repeat length","volume":"76","author":"Chutake","year":"2014","journal-title":"Ann Neurol."},{"issue":"9","key":"10.1007\/s13311-019-00764-x_bib64","doi-asserted-by":"crossref","first-page":"e0138437","DOI":"10.1371\/journal.pone.0138437","article-title":"FXN promoter silencing in the humanized mouse model of Friedreich ataxia","volume":"10","author":"Chutake","year":"2015","journal-title":"PLoS One."},{"issue":"24","key":"10.1007\/s13311-019-00764-x_bib65","first-page":"6932","article-title":"Expanded GAA repeats impede transcription elongation through the FXN gene and induce transcriptional silencing that is restricted to the FXN locus","volume":"24","author":"Li","year":"2015","journal-title":"Hum Mol Genet."},{"issue":"3","key":"10.1007\/s13311-019-00764-x_bib66","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrm2854","article-title":"Repeat instability as the basis for human diseases and as a potential target for therapy","volume":"11","author":"Lopez Castel","year":"2010","journal-title":"Nat Rev Mol Cell Biol."},{"issue":"35","key":"10.1007\/s13311-019-00764-x_bib67","doi-asserted-by":"crossref","first-page":"29861","DOI":"10.1074\/jbc.M112.391961","article-title":"Role of mismatch repair enzymes in GAA.TTC triplet-repeat expansion in Friedreich ataxia induced pluripotent stem cells","volume":"287","author":"Du","year":"2012","journal-title":"J Biol Chem."},{"issue":"5","key":"10.1007\/s13311-019-00764-x_bib68","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/gt.2016.89","article-title":"Deletion of the GAA repeats from the human frataxin gene using the CRISPR-Cas9 system in YG8R-derived cells and mouse models of Friedreich ataxia","volume":"24","author":"Ouellet","year":"2017","journal-title":"Gene Ther."},{"issue":"6","key":"10.1007\/s13311-019-00764-x_bib69","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/mt.2015.41","article-title":"Excision of expanded GAA repeats alleviates the molecular phenotype of Friedreich's ataxia","volume":"23","author":"Li","year":"2015","journal-title":"Mol Ther."},{"key":"10.1007\/s13311-019-00764-x_bib70","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1074\/jbc.RA118.006515","article-title":"Transcription profiling of isogenic Friedreich ataxia neurons and effect of an HDAC inhibitor on disease signatures","volume":"294","author":"Lai","year":"2019","journal-title":"J Biol Chem."},{"issue":"1","key":"10.1007\/s13311-019-00764-x_bib71","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/jgm.320","article-title":"Upregulation of expression from the FRDA genomic locus for the therapy of Friedreich ataxia","volume":"5","author":"Sarsero","year":"2003","journal-title":"J Gene Med."},{"issue":"1","key":"10.1007\/s13311-019-00764-x_bib72","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1128\/MCB.26.1.28-38.2006","article-title":"Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage","volume":"26","author":"Solomon","year":"2006","journal-title":"Mol Cell Biol."},{"key":"10.1007\/s13311-019-00764-x_bib73","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.chembiol.2009.07.010","article-title":"Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing","volume":"16","author":"Xu","year":"2009","journal-title":"Chem Biol."},{"key":"10.1007\/s13311-019-00764-x_bib74","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0140-6736(14)60382-2","article-title":"Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study.","volume":"384","author":"Libri","year":"2014","journal-title":"Lancet"},{"issue":"25","key":"10.1007\/s13311-019-00764-x_bib75","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1093\/hmg\/ddt370","article-title":"A GAA repeat expansion reporter model of Friedreich's ataxia recapitulates the genomic context and allows rapid screening of therapeutic compounds","volume":"22","author":"Lufino","year":"2013","journal-title":"Hum Mol Genet."},{"key":"10.1007\/s13311-019-00764-x_bib76","doi-asserted-by":"crossref","first-page":"35402","DOI":"10.1074\/jbc.M807045200","article-title":"Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases","volume":"283","author":"Chou","year":"2008","journal-title":"J Biol Chem."},{"issue":"12","key":"10.1007\/s13311-019-00764-x_bib77","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.3390\/ph4121578","article-title":"Improved histone deacetylase inhibitors as therapeutics for the neurodegenerative disease Friedreich's ataxia: a new synthetic route","volume":"4","author":"Xu","year":"2011","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1007\/s13311-019-00764-x_bib78","doi-asserted-by":"crossref","first-page":"e8825","DOI":"10.1371\/journal.pone.0008825","article-title":"Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model","volume":"5","author":"Rai","year":"2010","journal-title":"PLoS One."},{"issue":"3","key":"10.1007\/s13311-019-00764-x_bib79","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.nbd.2011.02.016","article-title":"Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model","volume":"42","author":"Sandi","year":"2011","journal-title":"Neurobiol Dis."},{"key":"10.1007\/s13311-019-00764-x_bib80","first-page":"4847","article-title":"Friedreich ataxia induced pluripotent stem cell-derived neurons show a cellular phenotype that is corrected by a benzamide HDAC inhibitor","volume":"25","author":"Codazzi","year":"2016","journal-title":"Hum Mol Genet."},{"key":"10.1007\/s13311-019-00764-x_bib81","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkw107","article-title":"Reversal of epigenetic promoter silencing in Friedreich ataxia by a class I histone deacetylase inhibitor","author":"Chutake","year":"2016","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1007\/s13311-019-00764-x_bib82","doi-asserted-by":"crossref","first-page":"e55940","DOI":"10.1371\/journal.pone.0055940","article-title":"Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One."},{"issue":"5","key":"10.1007\/s13311-019-00764-x_bib83","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1007\/s00415-015-7719-2","article-title":"An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels","volume":"262","author":"Yiu","year":"2015","journal-title":"J Neurol."},{"issue":"1","key":"10.1007\/s13311-019-00764-x_bib84","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1089\/nat.2017.0703","article-title":"Activation of frataxin protein expression by antisense oligonucleotides targeting the mutant expanded repeat","volume":"28","author":"Li","year":"2018","journal-title":"Nucleic Acid Ther."},{"issue":"17","key":"10.1007\/s13311-019-00764-x_bib85","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1016\/j.bmcl.2018.07.033","article-title":"Activating frataxin expression by single-stranded siRNAs targeting the GAA repeat expansion","volume":"28","author":"Shen","year":"2018","journal-title":"Bioorg Med Chem Lett."},{"key":"10.1007\/s13311-019-00764-x_bib86","doi-asserted-by":"crossref","DOI":"10.1261\/rna.071290.119","article-title":"Efficient electroporation of neuronal cells using synthetic oligonucleotides: identifying duplex RNA and antisense oligonucleotide activators of human frataxin expression","author":"Shen","year":"2019","journal-title":"Rna."},{"key":"10.1007\/s13311-019-00764-x_bib87","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.omtn.2018.04.009","article-title":"Increased frataxin expression induced in Friedreich ataxia cells by platinum TALE-VP64s or platinum TALE-SunTag","volume":"12","author":"Cherif","year":"2018","journal-title":"Molecular Therapy Nucleic Acids."},{"key":"10.1007\/s13311-019-00764-x_bib88","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-1-4939-7774-1_2","article-title":"Zinc fingers, TALEs, and CRISPR Systems: a comparison of tools for epigenome editing","volume":"1767","author":"Waryah","year":"2018","journal-title":"Methods Mol Biol."},{"issue":"1","key":"10.1007\/s13311-019-00764-x_bib89","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0022-2836(02)00430-8","article-title":"Structure of a beta-alanine-linked polyamide bound to a full helical turn of purine tract DNA in the 1:1 motif","volume":"320","author":"Urbach","year":"2002","journal-title":"J Mol Biol."},{"key":"10.1007\/s13311-019-00764-x_bib90","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1038\/sj.emboj.7601125","article-title":"Displacement of D1, HP1 and topoisomerase II from satellite heterochromatin by a specific polyamide","volume":"25","author":"Blattes","year":"2006","journal-title":"Embo J."},{"key":"10.1007\/s13311-019-00764-x_bib91","doi-asserted-by":"crossref","first-page":"13039","DOI":"10.1073\/pnas.0806308105","article-title":"In vivo imaging of pyrrole-imidazole polyamides with positron emission tomography","volume":"105","author":"Harki","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"issue":"6370","key":"10.1007\/s13311-019-00764-x_bib92","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1126\/science.aan6414","article-title":"Synthetic transcription elongation factors license transcription across repressive chromatin","volume":"358","author":"Erwin","year":"2017","journal-title":"Science"},{"issue":"13","key":"10.1007\/s13311-019-00764-x_bib93","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1093\/hmg\/dds110","article-title":"Interferon gamma upregulates frataxin and corrects the functional deficits in a Friedreich ataxia model","volume":"21","author":"Tomassini","year":"2012","journal-title":"Hum Mol Genet."},{"issue":"1","key":"10.1007\/s13311-019-00764-x_bib94","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/ane.12337","article-title":"Open-label pilot study of interferon gamma-1b in Friedreich ataxia","volume":"132","author":"Seyer","year":"2015","journal-title":"Acta Neurologica Scandinavica"},{"issue":"3","key":"10.1007\/s13311-019-00764-x_bib95","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/acn3.731","article-title":"Randomized, double-blind, placebo-controlled study of interferon-gamma 1b in Friedreich ataxia","volume":"6","author":"Lynch","year":"2019","journal-title":"Annals of Clinical and Translational Neurology"},{"key":"10.1007\/s13311-019-00764-x_bib96","doi-asserted-by":"crossref","DOI":"10.1089\/ars.2012.4537","article-title":"Frataxin deficiency leads to defects in expression of antioxidants and Nrf2 expression in dorsal root ganglia of the Friedreich's ataxia YG8R mouse model.","author":"Shan","year":"2013","journal-title":"Antioxid Redox Signal."},{"issue":"4","key":"10.1007\/s13311-019-00764-x_bib97","doi-asserted-by":"crossref","first-page":"7853","DOI":"10.3390\/ijms14047853","article-title":"Frataxin deficiency leads to reduced expression and impaired translocation of NF-E2-related factor (Nrf2) in cultured motor neurons","volume":"14","author":"D'Oria","year":"2013","journal-title":"International Journal of Molecular Sciences."},{"issue":"25","key":"10.1007\/s13311-019-00764-x_bib98","doi-asserted-by":"crossref","first-page":"6848","DOI":"10.1093\/hmg\/ddu408","article-title":"Dyclonine rescues frataxin deficiency in animal models and buccal cells of patients with Friedreich's ataxia","volume":"23","author":"Sahdeo","year":"2014","journal-title":"Hum Mol Genet."},{"issue":"10","key":"10.1007\/s13311-019-00764-x_bib99","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18102173","article-title":"Nrf2-inducers counteract neurodegeneration in frataxin-silenced motor neurons: disclosing new therapeutic targets for Friedreich's ataxia.","volume":"18","author":"Petrillo","year":"2017","journal-title":"International Journal of Molecular Sciences."},{"key":"10.1007\/s13311-019-00764-x_bib100","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fncel.2018.00188","article-title":"Novel Nrf2-inducer prevents mitochondrial defects and oxidative stress in Friedreich's ataxia models","volume":"12","author":"Abeti","year":"2018","journal-title":"Frontiers in Cellular Neuroscience."},{"issue":"15","key":"10.1007\/s13311-019-00764-x_bib101","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1093\/hmg\/ddx167","article-title":"Dimethyl fumarate mediates Nrf2-dependent mitochondrial biogenesis in mice and humans","volume":"26","author":"Hayashi","year":"2017","journal-title":"Hum Mol Genet."},{"issue":"4","key":"10.1007\/s13311-019-00764-x_bib102","doi-asserted-by":"crossref","first-page":"e0153574","DOI":"10.1371\/journal.pone.0153574","article-title":"Lymphoblast oxidative stress genes as potential biomarkers of disease severity and drug effect in Friedreich's ataxia","volume":"11","author":"Hayashi","year":"2016","journal-title":"PLoS One."},{"issue":"6","key":"10.1007\/s13311-019-00764-x_bib103","doi-asserted-by":"crossref","first-page":"e0217776","DOI":"10.1371\/journal.pone.0217776","article-title":"Dimethyl fumarate dosing in humans increases frataxin expression: a potential therapy for Friedreich's ataxia","volume":"14","author":"Jasoliya","year":"2019","journal-title":"PLoS One."},{"issue":"1","key":"10.1007\/s13311-019-00764-x_bib104","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/acn3.660","article-title":"Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia","volume":"6","author":"Lynch","year":"2019","journal-title":"Annals of Clinical and Translational Neurology."},{"issue":"11","key":"10.1007\/s13311-019-00764-x_bib105","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1365-2362.2005.01568.x","article-title":"Recombinant human erythropoietin: effects on frataxin expression in vitro","volume":"35","author":"Sturm","year":"2005","journal-title":"Eur J Clin Invest."},{"issue":"3","key":"10.1007\/s13311-019-00764-x_bib106","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s12311-008-0036-x","article-title":"Recombinant human erythropoietin increases frataxin protein expression without increasing mRNA expression","volume":"7","author":"Acquaviva","year":"2008","journal-title":"Cerebellum"},{"key":"10.1007\/s13311-019-00764-x_bib107","doi-asserted-by":"crossref","first-page":"10526","DOI":"10.1073\/pnas.97.19.10526","article-title":"Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury","volume":"97","author":"Brines","year":"2000","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5","key":"10.1007\/s13311-019-00764-x_bib108","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/ana.21177","article-title":"Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin","volume":"62","author":"Boesch","year":"2007","journal-title":"Ann Neurol."},{"issue":"3","key":"10.1007\/s13311-019-00764-x_bib109","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/mds.24066","article-title":"Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial","volume":"27","author":"Mariotti","year":"2012","journal-title":"Mov Disord."},{"issue":"5","key":"10.1007\/s13311-019-00764-x_bib110","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/mds.26552","article-title":"Long-term effect of epoetin alfa on clinical and biochemical markers in Friedreich ataxia","volume":"31","author":"Sacca","year":"2016","journal-title":"Mov Disord."},{"issue":"7","key":"10.1007\/s13311-019-00764-x_bib111","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/mds.25836","article-title":"Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia","volume":"29","author":"Boesch","year":"2014","journal-title":"Mov Disord."},{"key":"10.1007\/s13311-019-00764-x_bib112","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.neuropharm.2017.05.011","article-title":"Erythropoietin and small molecule agonists of the tissue-protective erythropoietin receptor increase FXN expression in neuronal cells in vitro and in FXN-deficient KIKO mice in vivo","volume":"123","author":"Miller","year":"2017","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1007\/s13311-019-00764-x_bib113","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/mds.27604","article-title":"Drug repositioning screening identifies etravirine as a potential therapeutic for Friedreich's ataxia","volume":"34","author":"Alfedi","year":"2019","journal-title":"Mov Disord."},{"key":"10.1007\/s13311-019-00764-x_bib114","doi-asserted-by":"crossref","first-page":"39738","DOI":"10.1038\/srep39738","article-title":"Antiretroviral treatment with efavirenz disrupts the blood-brain barrier integrity and increases stroke severity","volume":"6","author":"Bertrand","year":"2016","journal-title":"Sci Rep."},{"key":"10.1007\/s13311-019-00764-x_bib115","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/hmg\/ddr554","article-title":"A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse model","volume":"21","author":"Vyas","year":"2012","journal-title":"Hum Mol Genet."},{"issue":"5","key":"10.1007\/s13311-019-00764-x_bib116","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nm.3510","article-title":"Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia","volume":"20","author":"Perdomini","year":"2014","journal-title":"Nat Med."},{"key":"10.1007\/s13311-019-00764-x_bib117","article-title":"Correction of half the cardiomyocytes fully rescue Friedreich ataxia mitochondrial cardiomyopathy through cell-autonomous mechanisms","author":"Belbellaa","year":"2018","journal-title":"Hum Mol Genet."},{"issue":"8","key":"10.1007\/s13311-019-00764-x_bib118","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.ymthe.2018.05.006","article-title":"Rapid and complete reversal of sensory ataxia by gene therapy in a novel model of Friedreich ataxia","volume":"26","author":"Piguet","year":"2018","journal-title":"Mol Ther."},{"key":"10.1007\/s13311-019-00764-x_bib119","doi-asserted-by":"crossref","first-page":"14044","DOI":"10.1038\/mtm.2014.44","article-title":"An AAV9 coding for frataxin clearly improved the symptoms and prolonged the life of Friedreich ataxia mouse models","volume":"1","author":"Gerard","year":"2014","journal-title":"Molecular Therapy Methods & Clinical Development"},{"issue":"11","key":"10.1007\/s13311-019-00764-x_bib120","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/jgm.2993","article-title":"Sustained FXN expression in dorsal root ganglia from a nonreplicative genomic HSV-1 vector","volume":"19","author":"Ventosa","year":"2017","journal-title":"J Gene Med."},{"key":"10.1007\/s13311-019-00764-x_bib121","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.copbio.2019.01.002","article-title":"Engineering the AAV capsid to evade immune responses","volume":"60","author":"Barnes","year":"2019","journal-title":"Current opinion in biotechnology."},{"key":"10.1007\/s13311-019-00764-x_bib122","doi-asserted-by":"crossref","first-page":"20019","DOI":"10.1038\/srep20019","article-title":"Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich's ataxia","volume":"6","author":"Nabhan","year":"2016","journal-title":"Sci Rep."},{"issue":"7","key":"10.1007\/s13311-019-00764-x_bib123","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/hmg\/ddq566","article-title":"Preventing the ubiquitin-proteasome-dependent degradation of frataxin, the protein defective in Friedreich's ataxia","volume":"20","author":"Rufini","year":"2011","journal-title":"Hum Mol Genet."},{"key":"10.1007\/s13311-019-00764-x_bib124","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.nbd.2014.12.011","article-title":"Highly specific ubiquitin-competing molecules effectively promote frataxin accumulation and partially rescue the aconitase defect in Friedreich ataxia cells","volume":"75","author":"Rufini","year":"2015","journal-title":"Neurobiol Dis."},{"issue":"8","key":"10.1007\/s13311-019-00764-x_bib125","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/j.celrep.2017.01.079","article-title":"E3 ligase RNF126 directly ubiquitinates frataxin, promoting its degradation: identification of a potential therapeutic target for Friedreich ataxia","volume":"18","author":"Benini","year":"2017","journal-title":"Cell Rep"},{"issue":"15","key":"10.1007\/s13311-019-00764-x_bib126","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1093\/hmg\/ddv162","article-title":"Src inhibitors modulate frataxin protein levels","volume":"24","author":"Cherubini","year":"2015","journal-title":"Hum Mol Genet."},{"issue":"1","key":"10.1007\/s13311-019-00764-x_bib127","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/mt.2014.143","article-title":"Mesenchymal stem cells improve motor functions and decrease neurodegeneration in ataxic mice","volume":"23","author":"Jones","year":"2015","journal-title":"Mol Ther."},{"issue":"4","key":"10.1007\/s13311-019-00764-x_bib128","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s12311-017-0860-y","article-title":"Mesenchymal stem cell-derived factors restore function to human frataxin-deficient cells","volume":"16","author":"Kemp","year":"2017","journal-title":"Cerebellum."},{"issue":"413","key":"10.1007\/s13311-019-00764-x_bib129","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj2347","article-title":"Transplantation of wild-type mouse hematopoietic stem and progenitor cells ameliorates deficits in a mouse model of Friedreich's ataxia.","volume":"9","author":"Rocca","year":"2017","journal-title":"Sci Transl Med."},{"issue":"4","key":"10.1007\/s13311-019-00764-x_bib130","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/ana.25207","article-title":"Bone marrow transplantation stimulates neural repair in Friedreich's ataxia mice","volume":"83","author":"Kemp","year":"2018","journal-title":"Ann Neurol."},{"issue":"2","key":"10.1007\/s13311-019-00764-x_bib131","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ana.24846","article-title":"Cytokine therapy-mediated neuroprotection in a Friedreich's ataxia mouse model","volume":"81","author":"Kemp","year":"2017","journal-title":"Ann Neurol."},{"key":"10.1007\/s13311-019-00764-x_bib132","doi-asserted-by":"crossref","first-page":"e2237","DOI":"10.1038\/cddis.2016.111","article-title":"Mitochondrial energy imbalance and lipid peroxidation cause cell death in Friedreich's ataxia","volume":"7","author":"Abeti","year":"2016","journal-title":"Cell death & disease."},{"key":"10.1007\/s13311-019-00764-x_bib133","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.redox.2013.06.004","article-title":"Insights into the role of oxidative stress in the pathology of Friedreich ataxia using peroxidation resistant polyunsaturated fatty acids","volume":"1","author":"Cotticelli","year":"2013","journal-title":"Redox Biology"},{"issue":"6","key":"10.1007\/s13311-019-00764-x_bib134","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/mds.27353","article-title":"Randomized, clinical trial of RT001: early signals of efficacy in Friedreich's ataxia","volume":"33","author":"Zesiewicz","year":"2018","journal-title":"Mov Disord."},{"key":"10.1007\/s13311-019-00764-x_bib135","doi-asserted-by":"crossref","DOI":"10.1007\/s13311-018-00706-z","article-title":"Phosphodiesterase inhibitors revert axonal dystrophy in Friedreich's ataxia mouse model. Neurotherapeutics : the journal of the American Society for Experimental","author":"Molla","year":"2019","journal-title":"NeuroTherapeutics."},{"issue":"8","key":"10.1007\/s13311-019-00764-x_bib136","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1586\/14737175.2014.939173","article-title":"Therapeutic approaches for the treatment of Friedreich's ataxia","volume":"14","author":"Strawser","year":"2014","journal-title":"Expert Rev Neurother."},{"issue":"10","key":"10.1007\/s13311-019-00764-x_bib137","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/hmg\/ddh114","article-title":"Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia","volume":"13","author":"Seznec","year":"2004","journal-title":"Hum Mol Genet."},{"key":"10.1007\/s13311-019-00764-x_bib138","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s00415-011-6174-y","article-title":"Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study","volume":"259","author":"Meier","year":"2012","journal-title":"J Neurol."},{"key":"10.1007\/s13311-019-00764-x_bib139","doi-asserted-by":"crossref","DOI":"10.1111\/ane.13088","article-title":"Patient reported outcomes in Friedreich's ataxia after withdrawal from idebenone","author":"Cook","year":"2019","journal-title":"Acta Neurologica Scandinavica."},{"issue":"9","key":"10.1007\/s13311-019-00764-x_bib140","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1039\/C8MD00274F","article-title":"Phenothiazine antioxidants increase mitochondrial biogenesis and frataxin levels in Friedreich's ataxia cells","volume":"9","author":"Khdour","year":"2018","journal-title":"MedChemComm."},{"issue":"4","key":"10.1007\/s13311-019-00764-x_bib141","doi-asserted-by":"crossref","first-page":"e34600","DOI":"10.1371\/journal.pone.0034600","article-title":"Estrogen prevents oxidative damage to the mitochondria in Friedreich's ataxia skin fibroblasts","volume":"7","author":"Richardson","year":"2012","journal-title":"PLoS One."},{"key":"10.1007\/s13311-019-00764-x_bib142","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2050-6511-13-12","article-title":"R- and S-equol have equivalent cytoprotective effects in Friedreich's ataxia","volume":"13","author":"Richardson","year":"2012","journal-title":"BMC pharmacology & toxicology."},{"issue":"2","key":"10.1007\/s13311-019-00764-x_bib143","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s12311-008-0087-z","article-title":"PPAR-gamma agonist Azelaoyl PAF increases frataxin protein and mRNA expression: new implications for the Friedreich's ataxia therapy","volume":"8","author":"Marmolino","year":"2009","journal-title":"Cerebellum"},{"issue":"13","key":"10.1007\/s13311-019-00764-x_bib144","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1093\/hmg\/ddp183","article-title":"Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARgamma pathway as a therapeutic target in Friedreich's ataxia","volume":"18","author":"Coppola","year":"2009","journal-title":"Hum Mol Genet."},{"issue":"1","key":"10.1007\/s13311-019-00764-x_bib145","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2217\/nmt.15.73","article-title":"Emerging therapies in Friedreich's ataxia","volume":"6","author":"Aranca","year":"2016","journal-title":"Neurodegenerative disease management."},{"issue":"17","key":"10.1007\/s13311-019-00764-x_bib146","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1093\/hmg\/ddy198","article-title":"Peripheral blood gene expression reveals an inflammatory transcriptomic signature in Friedreich's ataxia patients","volume":"27","author":"Nachun","year":"2018","journal-title":"Hum Mol Genet."},{"issue":"3","key":"10.1007\/s13311-019-00764-x_bib147","doi-asserted-by":"crossref","first-page":"e0151026","DOI":"10.1371\/journal.pone.0151026","article-title":"Frataxin deficiency promotes excess microglial DNA damage and inflammation that is rescued by PJ34","volume":"11","author":"Shen","year":"2016","journal-title":"PLoS One"},{"key":"10.1007\/s13311-019-00764-x_bib148","doi-asserted-by":"crossref","DOI":"10.1002\/mus.26610","article-title":"Open label pilot study of oral methylprednisolone for the treatment of patients with friedreich ataxia","author":"Patel","year":"2019","journal-title":"Muscle & Nerve."}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-019-00764-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-019-00764-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923009662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923009662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-019-00764-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:47:57Z","timestamp":1761806877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923009662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":148,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1878747923009662"],"URL":"https:\/\/doi.org\/10.1007\/s13311-019-00764-x","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Mechanisms and Therapeutics for the GAA\u00b7TTC Expansion Disease Friedreich Ataxia","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-019-00764-x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}